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Pancreas ductal adenocarcinoma (PDAC) is a highly lethal cancer that
typically presents as advanced, unresectable disease. This invasive
tendency, coupled with intrinsic resistance to standard therapies and
genome instability, aremajor contributors to poor long-term survival.
The genetic elements governing the invasive propensity of PDAC
have not been well elucidated. Here, in the course of validating
resident genes in highly recurrent and focal amplifications in PDAC,
we have identified Rio Kinase 3 (RIOK3) as an amplified gene that
alters cytoskeletal architecture as well as promotes pancreatic ductal
cell migration and invasion. We determined that RIOK3 promotes its
invasive activities through activation of the small G protein, Rac. This
genomic and functional link to Rac signaling prompted a genome
wide survey of other components of the Rho family network, reveal-
ing p21 Activated Kinase 4 (PAK4) as another amplified gene in PDAC
tumors and cell lines. Like RIOK3, PAK4 promotes pancreas ductal cell
motility and invasion. Together, the genomic and functional profiles
establish the Rho family GTP-binding proteins as integral to the
hallmark invasive nature of this lethal disease.
Pak4  pancreatic cancer  Rac  Rio Kinase3
Pancreas ductal adenocarcinoma (PDAC) is a leading cause ofcancer death with a dismal 5 year survival (1). The rapid demise
of PDAC patients relates to detection of disease at advanced
inoperable stages and intense resistance to conventional and tar-
geted therapies (1, 2). Defining and validating the genetic aberra-
tions underlying PDAC genesis and progression, particularly those
governing its robust invasive and metastatic tendencies, remains a
critical area for active investigation. Molecular genetic studies have
defined an expanding atlas of highly recurrent genetic events in
PDAC including activating mutations in the KRAS oncogene and
epigenetic and/or mutational extinction of the INK4a, p53, and
SMAD4 tumor suppressor genes. That these events contribute to
PDAC pathogenesis is evident from genetically engineered mouse
models, demonstrating key roles of activated KRAS in disease
genesis and loss of the aforementioned tumor suppressors in
malignant progression (reviewed in ref. 3). In addition, array-
comparative genomic hybridization (aCGH) as well as other whole
genome analysis techniques has revealed many amplifications and
deletions in PDAC (4–12).Many of these copy number aberrations
(CNAs) appear to be relevant to the pathogenesis of PDAC as
inferred from their highly recurrent nature and presence of known
cancer genes in some loci. However, for the majority of loci, there
remains the need to identify and validate the relevant cancer
gene(s), to define their linked signaling pathways, and to determine
how these genetic lesions govern the characteristic tumor biological
properties of this lethal disease. In this study, we performed
high-resolution aCGH to better define the atlas of recurrent CNAs
in PDAC, particularly those that might contribute to the highly
invasive and metastatic nature of this disease. These genomic and
functional validation studies support a role for the Rho family of
GTP-binding proteins in PDAC invasiveness.
Results
Atypical Kinase, RIOK3, Is a Target of Recurrent Amplification and
Overexpression in PDAC. High resolution aCGH and bioinformatic
analysis identified recurrent copy number alterations (CNAs) in a
collection of 14 human PDAC tumors and 15 cell lines [Fig. 1A and
supporting information (SI) Table S1] (42). Among the most
notable CNAs in our dataset is a highly recurrent, focal and high
amplitude amplicon targeting 18q11. Using a combination of
tumors, the minimal common region (MCR) of amplification was
delimited to a 2-Mb span harboring eight characterized genes, and
two conserved ORFs (Fig. 1 A and B). Tumor microarray fluores-
cence in situ hybridization (TMA-FISH) was performed to assess
recurrence in a larger panel of PDAC tumor samples.Using a probe
within the 18q amplicon, six of 38 (16%) informative tumor cores
showed definitive gain/amplification (Fig. 1C). The 18q11 amplicon
was also prioritized for in-depth analysis based on its recurrence
across multiple tumor types. Specifically, array-CGH profiles
showed recurrent gains in nonsmall cell lung cancer (18/63, 28.6%),
colorectal adenocarcinoma (8/74, 10.8%),melanoma (9/123, 7.3%),
and pancreatic cancer (7/30, 23.3%). Gene expression levels can
correlate with gene copy number (13), prompting examination of
MCR resident gene expression in relation to amplification status.
Two of the eight MCR resident genes were excluded upfront, as
Cables1 is a tumor suppressor (14, 15) and CTAGE1 showed
minimal or absent mRNA expression in the PDAC cell lines tested
(data not shown). The remaining eight genes were analyzed in our
panel of 20PDACcell lines and their expressionwas comparedwith
that of an immortalized human pancreatic ductal cell line. Quan-
titative real-time reverse transcriptase PCR (qRT-PCR) revealed
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that several known genes as well as uncharacterized ORFs showed
varying levels of overexpression in samples with amplification (Fig.
1D). We were initially interested in RIOK3 as it is a kinase that has
not been characterized. This, along with the fact that it appears to
be both amplified and overexpressed, made RIOK3 an attractive
candidate on which to focus further characterization and mecha-
nistic analyses. The overexpression of RIOK3 seen by qPCR was
confirmed by western blot analyses (Fig. 1E). Given the presence
of this amplification in a significant proportion of tumors, we
assessed whether any potential somatic mutations were present in
RIOK3 that could lead to its activation. Sequence analysis of the
coding region of RIOK3 in a collection of 16 primary tumors and
21 cell lines detected one homozygous, nonsynonymousmutation in
a PDAC cell line, HPAFII. This variant, resulted in the change of
a serine residue to a leucine (S447L) in the conservedRIO domain.
In summary, these multidimensional data implicated RIOK3 as a
potential target of the 18q11 amplification in PDAC and multiple
other tumor types.
Functional Analysis of RIOK3. Loss-of-function studies were per-
formed to determine the oncogenic relevance of those genes that
showed overexpression using 8898T cells that harbor the 18q
amplification: GATA6, C18ORF45, RIOK3 and C18ORF8. Inter-
estingly, knockdown of each of these genes showed varying levels of
inhibition of colony formation (data not shown, Fig. 2A), implicat-
ing them as putative PDAC oncogenes. In particular, RIOK3
suppression resulted in a significant decrease in the ability to form
colonies in soft-agar as did siRNA-mediated knockdown of KRAS
and MAPK (Fig. 2A). Confirmatory RIOK3 shRNA knockdown
studies showed decreased soft agar growth that correlated with the
robustness of gene suppression (Fig. S1 A and B). Furthermore,
xenotransplants of 8988T cells with stable RIOK3 knockdown
resulted in reduced tumor growth, mirroring the soft agar findings
(Fig. 2B). In contrast to the decreased tumorigenicity in the
loss-of-function experiments, gain-of-function studies showed only
minimal activity for wild-type RIOK3 as well as its S447L variant
allele. Ectopic RIOK3 expression did not affect malignant trans-
formation of primary Ink4a/Arf null MEFs (16; data not shown)
and enforced RIOK3 expression in an immortalized human pan-
creatic ductal cell line did not alter the growth rate (Fig. S2A).
Finally, RIOK3 alone, or together with oncogenic KRAS, failed to
confer anchorage independence or tumorigenic potential on these
and other cell types (Fig. S2B; data not shown). Although RIOK3
showed minimal growth and transformation potential, enforced
expression produced a distinct morphological change characterized
by readily visible membrane alterations. As shown in Fig. 2C
whereas the control human pancreatic ductal cells were round and
displayed characteristic epithelial cell morphology (Upper Left),
RIOK3 expression promoted membrane architecture changes in
both pancreatic ductal cells (Upper) and immortalized mouse
embryo fibroblasts (Fig. 2C Lower) consisting of membrane ruf-
fling, cell flattening, and increased size. Correspondingly, RIOK3
knockdown strikingly altered the appearance of the 8988T cell line
morphology from small rounded cells with multiple protruding
edges (Fig. 2D Upper) to larger flattened cells with altered mem-
brane protrusions (Fig. 2D Lower). These morphological changes
and alteration of membrane architecture prompted assessment of
enforced RIOK3 expression on the motility of pancreatic ductal
cells. In the standard scratch assay, RIOK3-expressing pancreas
ductal lines exhibited accelerated migration into the cleared area
relative to controls (Fig. 2E). Additionally, in the modified Boyden
Chamber assay, RIOK3-expressing pancreatic ductal cells showed
increased migratory activity relative to controls (Fig. 2F). These
cells also exhibited an increased capacity to invade through Matri-
gel-coated membranes (Fig. 2G).
RIOK3-Induced Migration Involves the Small GTPase Rac. The small
GTPase, Rac, is a key regulator of lamellipodia formation and cell
motility (reviewed in refs. 17 and 18). The impact of RIOK3 on
these processes prompted us to assess whether Rac is a critical
downstream effector. In standard Rac activation pull-down assays,
RIOK3 expression led to accumulation of GTP-bound activated
endogenous Rac (Fig. 3A). As a first step to elucidate the connec-
tion to its cell morphology and motility phenotypes, we attempted
to determine whether RIOK3 was in complex with any known
proteins that play a role in these processes. Our initial focus was on
three proteins, PAK1, betaPIX, and GIT1 as RIOK1 was previ-
ously found in complex with these proteins (19). Whereas, RIOK3
interaction was not detectable with betaPix and GIT1, it was found
in complex with PAK1, which is a key downstream effector of Rac
(17, 18) (Fig. 3B; data not shown). Consistent with a RIOK3 link
to Rac signaling, treatment of pancreas ductal cells with a Rac
inhibitor, NSC23766 (20), was able to reverse the RIOK3-induced
morphological changes to a more rounded morphology character-
istic of control cells (Fig. 3C). Furthermore, Rac inhibition by
pharmacological means (Fig. 3D) or by dominant-negative inter-
ference (Fig. 3E) decreased theRIOK3-dependent pancreas ductal
cell migration through transwell chambers. Together, these data
support the view that RIOK3 promotes cell migration through the
activation of Rac. To determine whether the RIOK3 directed
activities are dependent on its kinase activity, we engineered two
different mutations that would be expected to abrogate its kinase
activity based on the structure/function analysis of bacterial and
yeast RIOK1 and 2 (21, 22). Interestingly, neither the D406N nor
the K290R mutant appeared to diminish RIOK3-induced activa-
tion of Rac (Fig. 3A) and these mutants appeared to retain
promigratory activity in pancreatic ductal cells (data not shown).
Fig. 1. Analysis of the 18q11 minimal common region. (A) (Top) Minimum
common region (within green dotted lines) of the RIOK3 amplicon in two
tumors, in blue and red. Dots are normalized log2 ratio for each probe; lines
are segmented log2 ratios in the region. (Middle) expanded region on chro-
mosome 18 showing ARI (Abberation Recurrence Index, a summation of log2
ratios from all samples for each probe) for both amplification/gain and
deletion/loss with the probe index on the x-axis. (Bottom) ARI for whole
chromosome 18. (B) Schematic of the minimal 18q11.2 amplicon (C) Tumor
microarray fluorescence in situ hybridization (TMA-FISH) using a probe within
the amplified genomic region labeled with FITC (green) and centromere
reference probe with Cy3 (red). Amplification is indicated by an increase in
ratio of green to red signals. Shown are four different tumor cores with
amplification. White arrow shows a nucleus with increased signal. (D) quan-
titative real time PCR (qRT-PCR) was performed with 20 PDAC cell lines and a
human pancreatic ductal cell line as a reference. The x-axis shows the resident
genes and relative expression is on the y-axis. The two lines that harbor the 18q
amplicon (8988T and 8988S) are boxed in cases of overexpression. (E) Western
blot confirming RIOK3 overexpression in pancreatic tumor lines. (HPDE, hu-
man pancreatic ductal cells).






Furthermore, the RIOK3 S447L PDAC variant allele, which alters
the RIO domain (containing the kinase signature motif) did not
significantly have an impact on Rac activation or cell migration
above that of the wild-type RIOK3 protein (Fig. 3 A, D, and E).
Together, these data indicate that RIOK3-induced activation of
Rac and enhanced cellmigrationmay not be dependent on an intact
kinase domain. Finally, we assessed whether enforced RIOK3
would alter the invasive properties of Panc1 cells, which typically
generate poorly invasive xenograft tumors and express low levels of
endogenous RIOK3 (Fig. 1E). RIOK3- and vector-transduced
tumors were allowed to reach 1 cm in greatest dimension and
harvested to assess the extent of invasion into the muscle. RIOK3-
transduced tumors exhibited greater invasive potential relative to
vector-transduced controls (Fig. 3F). This in vivo activity, together
with enhanced invasion and migration profile in cell culture,
supports a role for RIOK3 in PDAC tumor cell invasion.
Genomic Alterations of Rho Family Pathway Components in PDAC. The
identification of RIOK3 as a mediator of pancreatic ductal cell
migration and invasion and its link to the small GTPase, Rac,
prompted investigation of the genomic status of other genes in this
family in PDAC. Examination of downstream kinases of the Rho
family members Rac, Rho, and Cdc42 (Table S2) revealed ampli-
fication of PAK4 in primary tumors and cell lines. (Fig. 4A).
Confirmatory TMA-FISH showed evidence of gain/amplification
in 14 of 63 (22%) of PDAC specimens (Fig. 4B) as well as 14/50
(28%) prostate, 20/59 (34%) lung, 20/60 (33.3%) ovary, 4/18 (22%)
melanoma, 9/76 (11.8%) colon, and 4/27 (14.8%) liver carcinomas
(data not shown). RT-qPCR showed elevated PAK4 expression in
multiple lines including those with and without amplification,
suggesting multiple mechanisms, in addition to copy number,
driving increased PAK4 expression (Fig. 4C). Western blot analysis
confirmed over expression of PAK4 in multiple cell lines (Fig. 4C).
To assess PAK4 in PDAC biology, PAK4 knockdown was per-
formed in 8988T cells that show PAK4 amplification and robust
expression. shRNA-mediated knockdown resulted in a significant
reduction in anchorage independent growth relative to controls and
ineffective PAK4 shRNAs (Fig. 5 A and B). Additionally, expres-
sion of an activated PAK4 mutant (25) in pancreatic ductal cells
caused an elongated morphology in a significant fraction cells
consistent with altered cytoskeletal dynamics as has been reported
previously in rodent fibroblasts (23) (Fig. 5C). These cytoskeletal
changes prompted gain-of-function studies to assess the impact of
wild-type and activated mutant forms of PAK4 on migration and
invasion of pancreatic ductal cells. While wild-type PAK4 express-
ing ductal cells showed only minimal migratory enhancement,
activated PAK4 produced an increase in migratory capacity
through transwell chambers as well as increased invasion (Fig. 5 D
andE). Reciprocally, PAK4 siRNA-transfected 8988T cells showed
significantly diminished invasion compared with control siRNA-
transfectants (Fig. 5F). Similar observations were generated with
PAK4 shRNAs (data not shown). Together, the genomic and
functional data support a role for PAK4 in PDAC cellular migra-
tion and invasion.
Discussion
In this study, aCGH analysis of human PDAC led to the identifi-
cation of two genes, RIOK3 and PAK4, that are genomically
amplified in PDAC and other human tumors and appear to have
roles in tumor cell motility and invasion. Importantly, our findings
serve to link the Rho family of GTPases to PDAC pathobiology,
particularly its hallmark invasive activity. Although our data sup-
port RIOK3 and PAK4 as targets of their respective amplicons, the
complexity of the genome certainly allows for the possibility of
additional genes on these loci that contribute to PDAC tumori-
genesis. In this regard, there are two microRNAs on the 18q11
amplicon (MIRN1–2 andMIRN133A1) that could potentially play
a role in PDAC biology. In further support of the idea that multiple
genes on an amplicon may be functionally important, a report
published during the preparation of this manuscript demonstrated
that GATA6, present on the 18q11 amplicon, may also be a PDAC
oncogene (26). Our data are consistent with these findings and
Fig. 2. Functional analysis of RIOK3 in PDAC and
immortalized human pancreatic ductal cells. (A)
8988T cells were transfected with two different
siRNAs for RIOK3 (a and b) and controls (scrambled
or a cy3 labeled control) and seeded into semisolid
agar. Note the significant reduction of colonies of
significant size as well as that of the KRAS and
MAPK siRNAs when compared with the control
scrambled siRNA (quantitation below). (B) 8988T
cells transduced with RIOK3 shRNAs were injected
s.c. into the flanks of nude mice. Tumor weights
were plotted for each cohort. Horizontal lines rep-
resent the mean weight for the cohort. Xenografts
derived from cells with highly efficient knockdown
of RIOK3 (sh1) demonstrated a greater reduction in
weight as compared with that with a less robust
knockdown (sh2) and that of control tumors
(shGFP) (P0.05; t test). (C) Top right image depicts
immortalized human pancreatic ductal cells that
have enforced expression of RIOK3 and are stained
with rhodamine conjugated phalloidin to visualize
the actin cytoskeleton. Note the change in cell
morphology as compared with control cells (top
left), particularly in the larger flattened morphol-
ogy and development of membrane protrusions
(white arrow). The lower images show a similar phenomenon in immortalized MEFs (right image, with enforced RIOK3 expression). White bar, 5 m. Histogram
shows the quantitation of the number of pancreatic ductal cells with morphological changes with an increase as compared with control (P 0.001; Fisher Exact
Test). (D) 8988T cells were transduced with a lentiviral shRNA for RIOK3. The top 2 images show the normal morphology of control (shGFP) infected cells. The
bottom two images depict cells with RIOK3 knock down. As shown, these cells have a more flattened, enlarged shape with a decrease in cytoplasmic protrusions.
White bar, 5 m. (E) A scratch assay using pancreatic ductal cells either expressing a control vector (Top) or RIOK3 (Bottom) showing increased closure of the
scratched area in the RIOK3 expressing cells. (F) These same cells were used in transwell migration assays, showing increased cell migration in ductal cells with
enforced RIOK3 expression, which has been quantified in the graph below and expressed as fold of control cells. (G) Data from a representative experiment,
showing RIOK3 increases cell invasion in Matrigel coated wells compared with control ductal cells.
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additionally demonstrates that other genes such as C18ORF8 and
C18ORF45 show evidence of overexpression in lines harboring the
18q amplicon. Moreover, suppression of each of these genes,
including GATA6 as well as the 2 ORFs, causes a decrease in soft
agar colony growth. Further efforts to characterize these genes
either singly or in combination is certainly warranted given the
prevalence of this amplification in human cancers. Another point of
interest is that some tumor lines, such as 8988T contain the 18q as
well as the 19q amplicon (PAK4 locus) and further study of the
interaction of genes on multiple amplicons is of great interest.
The RIO proteins are members of the atypical protein kinase
family, given their lack of similarity to typical eukaryotic kinases.
RIO 1 and 2 proteins are conserved from archea to humans;
however, the RIO3 family is only seen in multicellular eukaryotes
(27, reviewed in refs. 28 and 29). RIO1 andRIO2 have been shown
to be essential genes in yeast as well as play a role in ribosome
biogenesis (30) andRIO1 is critical for proper cell cycle progression
(21). To this point, the function ofRIOK3has not been studied, nor
have its biochemical properties. RIOK3 expression has been ob-
served to be increased in metastatic Head and Neck cancers
compared with nonrecurrent tumors (31). RIOK3 is assumed to be
an active kinase, based on its sequence as well its relation to RIO1
and RIO2, which have been studied in yeast and bacteria and have
been crystallized (32, 33). To date, there are no knownphysiological
substrates of any of the RIO kinases, however RIO1 and 2 are
capable of autophosphorylation and can phosphorylate serine
Fig. 3. RIOK3 activates the small GTPase, Rac1. (A) 293T cells were trans-
fected with the indicated plasmids and Rac activation assays were performed.
The top panel shows the active (GTP-bound) fraction of Rac1 with increased
amounts in cells transfected with various RIOK3 constructs compared with the
control. Cells were triggered with serum or EGF as a positive control (last lane).
Total Rac1 expression (Middle) and RIOK3 (Lower) are shown as well. Histo-
grams are shown below showing GTP-Rac normalized to total Rac expression
by densitometric analysis and expressed as fold of control. The results from
separate experiments are depicted (Left and Right). Black and gray bars show
results from two representative assays. (B) Immunoprecipitation (IP) for HA-
RIOK3 in 293T cells either transfected with HA-RIOK3 or a control plasmid.
Western blotting was performed for endogenous PAK1. The blot on the left
shows the IP and the right shows whole cell lysate demonstrating the expres-
sion of endogenous PAK1. Note the enrichment of PAK1 that is brought down
in the RIOK3 transfected cells. HC, Ig heavy chain. (C) RIOK3-expressing human
pancreatic ductal cells were stained with phalloidin showing RIOK3 induced
membrane changes. Cells were treated with the Rac1 inhibitor NSC23766 (100
M) before staining (right column). These cells showed reversion of morphol-
ogy to that of the parental cells, with decreased membrane ruffling and
decrease in cell size. White bar, 5 m. (D) Transwell migration assays were
performed with the ductal cells as described previously. Cells were pretreated
with 50 M NSC23766 and the assay was performed in the presence of the
inhibitor. Inhibition of Rac1 decreased the RIOK3 induced migration of the cells
(right column). This is quantified below with black bars (untreated cells) and
gray bars (NSC23766) and expressed as fold of control. (E) Similar results were
obtained in cells coexpressing a dominant negative mutant of Rac1 (RacN17).
(F) Panc1 cells, which express low levels of RIOK3 were transduced with RIOK3
expression plasmids and injected into the flanks of immunocompromised
mice. Tumors were dissected en bloc when they reached 1 cm in greatest
dimension. The ability of the tumors (T) to invade from the s.c. tissue (SQ) into
the underlying muscle (M) was assessed histologically on H&E slides. The top
panels show a tumor derived from control Panc1 cells that remains confined
in the s.c. tissues at lower and higher magnification (scale bar, 200 m). The
bottom panels show a tumor from RIOK3 overexpressing cells that has invaded
into the surrounding muscle. The graph below shows that there is a statisti-
cally significant increase in the number of tumors that show muscle invasion
in the RIOK3 over expressing tumors (P 0.024, Fisher Exact Test) as compared
with tumors from control cells.
Fig. 4. PAK4 is amplified and overexpressed in PDAC. (A) (Top) Minimum
common region (within green dotted lines) of the PAK4 amplicon in one
tumor and one cell line, in blue and red. Dots are normalized log2 ratio for
each probes; lines are segmented log2 ratios in the region. (Middle) Expanded
region on chromosome 19 showing ARI (as above) for both amplification/gain
and deletion/loss. (Bottom) ARI for whole chromosome 19. (B) TMA-FISH using
a probe within the PAK4 amplicon labeled with Cy3 (red) and a centromere
reference probe labeled with FITC (green). Amplification is indicated by an
increase in ratio of red to green signals. Shown is a representative tumor core
with amplification. White arrow shows a nucleus with increased signal. (C)
qRT-PCR was performed with a panel PDAC cell lines and human pancreatic
ductal cell line as a reference to determine the relative expression of PAK4
across the lines. Results are expressed as fold over control (ductal cells marked
by the asterisks). Those with genomic amplification of this region (depicted by
pound symbols) all show marked overexpression. Western blot for PAK4
expression is shown below.






residues of artificial substrates (28, 29, 34). Importantly, RIO
kinases lack the ‘‘activation loop’’, which is thought to be essential
in all eukaryotic kinases to function (28, 29).Given this, it is possible
that these proteins may not function as kinases in eukaryotes.
Indeed, this idea is consistent with our data using kinase inactivat-
ing mutants, which show no abrogation of function in our assays.
The fact that we identified a sequence variant in the RIO domain
ofRIOK3 that does not appear to alter its function further supports
the concept that it is not acting as a kinase. Interestingly, this variant
has recently been reported to be a putative SNP that provides
another possible explanation as to why there are no obvious
differences between the wild-type and the S447L variant in our
assays. It is tempting to speculate that this gene, although struc-
turally related to RIO1 and 2, may have evolved in eukaryotes to
function more as a scaffolding protein and its kinase-related
sequences are a vestigial remnant.
Linking RIOK3 to Rac activation provides mechanistic insight
into its role in cytoskeletal and cell motility phenotypes. Interest-
ingly, whereas mutations analogous to that of activating Ras
mutations can also activate Rac, such mutations have not been
found in human tumors (35). Thus, amplification of RIOK3
appears to provide one mechanism through which Rac is activated
in multiple human tumors including PDAC. Interestingly, RIOK3
knockdown in the overexpressing 8988T PDAC line did not abro-
gate the ability of these cells to migrate or invade (data not shown),
suggesting possible redundancy in the signaling maintaining the
invasive phenotype. Given the well known complexities of Rac and
Rho signaling, this is certainly a possibility. The Rho family of
GTP-binding proteins consists of at least 20 members (reviewed in
ref. 17), which generally function as regulators of the actin cytoskel-
eton with complex interactions between family members and a
multitude of downstream effectors. Indeed, the finding that PAK4,
a downstream effector of CDC42 (36), was amplified extends these
findings to other members of this important gene family. Impor-
tantly, it has been demonstrated to be essential for Ras transfor-
mation and when activated by phosphomimetic point mutations,
can transform cells and cause alterations in the actin cytoskeleton
(23, 24). Recent data shows that wild-type PAK4 is capable of
transforming cells as well (41). The fact that knockdown of PAK4
expression in PDAC cell lines attenuates the invasive phenotype,
further underscores its importance in this disease and makes the
study of its role in PDAC highly relevant.
In conclusion, we have identified RIOK3 and PAK4 as
proinvasion genes in PDAC, further validating the use of tumor
genome profiling as a means for indentifying genetic elements
governing tumor pathobiology. Given the remarkable resistance
to therapy and the dismal prognosis of PDAC, these two genes
point to the Rho signaling pathway as a focus for future cancer
drug discovery efforts.
Methods
Cell Lines and Primary Tumors. Tumor cell lines were obtained from the American
Type Culture Collection (ATCC) or the German Collection of Microorganisms and
Cell Cultures (DSMZ). The establishment and characterization of the near normal
immortalized pancreatic duct epithelial (HPDE) cells were reported previously
(37,38).F-Actinwasvisualizedbystainingwithrhodamine-conjugatedphalloidin
(Sigma).Tenfieldsunder the20objectivewerecountedandthenumberofcells
with morphological changes scored. The Rac inhibitor, NSC23766, (Calbiochem)
was used at 50–100 M. Primary tumor samples were obtained from Memorial
Sloan Kettering Cancer Center and Brigham and Women’s Hospital tumor banks.
All were verified by H&E staining by an expert pathologist (G.C.C) and only those
with70% tumor cells were included.
Plasmids. The construction of RIOK3 expression plasmids was performed by
standard PCR based cloning approaches (see SIMethods). siRNAs were purchased
from IDT and transfected with Hiperfect (Qiagen) at a final concentration of
10–20 nM. Lentiviral shRNAs were obtained from the RNAi Consortium at the
Broad Institute (sequences available upon request). The PAK4 expression con-
structs (WT and the S445N activated mutant) were amplified from expression
Fig. 5. Knockdown and overexpression of
PAK4 reveals a potential role in PDAC biol-
ogy. (A) Western blot analysis showing
knockdown of PAK4 expression with various
shRNAs (top) with corresponding actin load-
ing control (bottom). (B) Results from soft
agar assays showing significant reduction in
number of colonies with PAK4 suppression
by shRNAs in 8988T cells. Results are quan-
tified below, showing reduction in colony
number as determined by Alamar blue stain-
ing and fluorescence intensity. (C) Human
pancreatic ductal cells expressing activated
Pak4 were fixed and stained with phalloidin,
as described previously. The left image de-
picts control cells, whereas the right image
shows an example of an elongated cell
(white arrow) in cells expressing the acti-
vated PAK4. White bar, 5 m. The histogram
shows a statistically significant difference
(Fisher Exact Test) in the number of elon-
gated cells in the activated PAK4 cells com-
pared with control cells. (D) Ductal cell lines
expressing activated or wild-type PAK4
were used for transwell migration assays.
Depicted here is an increase in cell invasion
with activated PAK4 cells (KA) shown on the
right, compared with control cells (left). Re-
sults are quantified below and expressed as
fold of control. (E) Similar experiments per-
formed in uncoated wells show an increase
in cell migration. (F) 8988T cells were trans-
fected with siRNAs directed to PAK4 and
invasion assays were performed. All three duplexes show significant reduction in invasion compared with control cells transfected with a control siRNA
(GFP) and are quantified below (expressed as fold of control).
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plasmids obtained from Dr. S. Gutkind (NIH/NIDCR, Bethesda, MD) and cloned in
frame with an N-terminal HA-tag into pBabe puro.
Expression Analysis. RNA was prepared from cell lines by standard methods and
reversetranscriptionwasperformedwithSuperScript II (Invitrogen)andoligo(dT)
priming. PCR primers were designed to amplify products of 100–150 bp within
target and control sequences (available upon request). Quantitative PCR was per-
formed on an Mx3000P cycler (Stratagene) using QuantiTect SYBR green (Qiagen).
Western blot analysis was performed via standard protocols. Antibodies against
RIOK3 (mouse monoclonal antibody: Abnova), HA-HRP (Sigma), Actin (Santa Cruz),
Rac1 (Millipore), PAK1 (Chemicon), -Pix (Millipore), and Git1 (Cell Signaling).
Invasion and Migration Assays. Modified Boyden chamber assays were per-
formed by using standard protocols with 24-well inserts—Matrigel coated
for invasion and uncoated for migration (Biocoat). Cells (200,000 –250,000)
were washed and then seeded in Opti-MEM (Invitrogen). The chemoat-
tractant was keratinocyte serum-free media  EGF and bovine pituitary
extract (Invitrogen). For inhibition of Rac1, cells were pretreated overnight
with 50 M NSC23766 and then seeded in the chambers in the presence of
the inhibitor. Scratch assays were performed in 6-well plates (see SI Meth-
ods).
Rac Activation Assay. To determine the activation state of Rac, pull down assays
were performed as per the manufacturer’s instructions (Upstate) using 293T cells
(see SI Methods).
Tumorigenicity Assays. Soft agar assays were performed in duplicate or
triplicate in 6 well plates per standard protocols (see SI Methods). For in
vivo tumorigenicity assays, 106 PDAC cells were injected s.c. into flanks of
NCr nude mice (Taconic). Tumorsizewasmeasuredbycaliper.Formuscle invasion
studiesofxenografts,tumorswereharvestedwhentheyreachedapproximately1cm
in the greatest dimension with a wide enbloc resection to preserve tissue architec-
ture.Muscle invasionwas scoredbyapathologistwhowasblindedtothe identityof
thesamples(G.C.C.).AllanimalexperimentswereapprovedbyIACUCunderProtocol
No. 04–114.
aCGH. Genomic DNAs from cell lines and primary tumors were extracted accord-
ing to the manufacturer’s instructions (Gentra Systems). Genomic DNA was
fragmented, random-prime labeled and hybridized to human oligonucleotide
microarrays as described (39). Raw aCGH profiles were processed to identify
statistically significant transitions in copy number by using a segmentation algo-
rithm (40). Significant copy-number changes were determined on the basis of
segmented profiles only (SI Methods).
Fluorescence in Situ Hybridization. Tissue microarrays were purchased from
Cybrdi or US Biomax. Fluorescence in situhybridization was performed following
standard protocols. BAC RP11–606B16 was used as a marker for the 18q11
amplicon (chr.18, 18M) and RP11–208H9 as a marker of the 19q13 amplicon
(chr.19, 44M). Centromere-specific probes (Abbott Labs) served as ploidy refer-
ences (SI Methods).
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